Physician profile
Rigardy P Munoz
NPI 1427092972
$6,953.04
in general payments reported to CMS, 2019-2025
27 companies · $847 in 2025
The $847 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $693 · 2021: $1,376 · 2022: $1,175 · 2023: $846 · 2024: $524 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $656.31 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $619.14 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $614.83 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $606.44 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $550.70 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $519.94 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $506.30 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $461.85 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $362.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.15 | 2019-2025 | Trintellix |
| Corium, LLC | $346.10 | 2021-2024 | Azstarys |
| Lundbeck LLC | $303.82 | 2019-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $167.31 | 2019-2022 | |
| Tris Pharma INC | $161.68 | 2020-2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $144.05 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $89.79 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $85.22 | 2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $65.51 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $63.75 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $49.14 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Adlon Therapeutics L.P. | $46.00 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $43.83 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.61 | 2025 | Cobenfy |
| Eisai INC. | $34.50 | 2020-2021 | |
| Indivior INC. | $27.02 | 2022 | |
| Noven Therapeutics, LLC | $16.82 | 2023 | Xelstrym |
| Shire North American Group INC | $15.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rigardy Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.